CAR Stock Recent News

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avis Budget Group, Inc ("Avis Budget" or the "Company") (NASDAQ: CAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Avis Budget Group, Inc. ("Avis Budget") (NASDAQ:CAR) concerning possible violations of federal securities laws. Avis Budget issued a press release on February 11, 2025, reporting its financial results for the fourth quarter and full year 2024.

LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Avis Budget Group, Inc. ("Avis Budget" or "the Company") (NASDAQ:CAR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avis Budget Group, Inc. ("Avis Budget" or "the Company") (NASDAQ:CAR). Investors who purchased Avis Budget securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CAR.

SHANGHAI , Feb. 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK, "CARsgen Therapeutics"), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces reaching agreements with an investment fund managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management Enterprise (Limited Partnership)  ("Zhuhai SB Xinchuang") to jointly invest in UCARsgen Biotech Limited ("UCARsgen"), a China-based new drug discovery biotechnology company focused on allogeneic CAR-T cell therapies for the treatment of hematologic malignancies. Under the agreements, UCARsgen has secured the exclusive rights in mainland China for the research, development, manufacture, and commercialization of the following allogeneic CAR-T products from CARsgen Therapeutics: the BCMA-targeted allogeneic CAR-T cell therapy for the treatment of multiple myeloma and plasma cell leukemia and the CD19/CD20 dual-targeted allogeneic

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model

NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Avis Budget Group, Inc. ("Avis Budget") (NASDAQ:CAR) concerning possible violations of federal securities laws. Avis Budget issued a press release on February 11, 2025, reporting its financial results for the fourth quarter and full year 2024.

NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avis Budget Group, Inc. ("Avis Budget" or "the Company") (NASDAQ:CAR). Investors who purchased Avis Budget securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CAR.

SAN JOSE, Calif. , Feb. 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is pleased to announce that its pioneering CAR-T therapy for ovarian cancer, developed in collaboration with Moffitt Cancer Center ("Moffitt"), was prominently featured in Breaking Cancer News in an article titled "Navigating Uncharted Territory: CAR-T for Ovarian Cancer.

Shares in Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) surged 13% in the first hour of trading after the company announced it had administered the first human dose of its experimental CAR-T cell therapy, HG-CT-1. The treatment is designed for adults with relapsed or treatment-resistant acute myeloid leukaemia, a condition with few options and a poor prognosis.